Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash from Operations (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Cash from Operations for 9 consecutive years, with 48698000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations changed N/A to 48698000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 46798000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at 46798000.0 for FY2025, 167.73% up from the prior year.
  • Cash from Operations for Q4 2025 was 48698000.0 at Soleno Therapeutics, up from 43500000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 48698000.0 in Q4 2025, with the low at 32752000.0 in Q1 2025.